scholarly journals Upregulation of glucosamine‑phosphate N‑acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma

2021 ◽  
Vol 21 (6) ◽  
Author(s):  
Pengyuan Zhu ◽  
Shaorui Gu ◽  
Haitao Huang ◽  
Chongjun Zhong ◽  
Zhenchuan Liu ◽  
...  
2019 ◽  
Vol 41 (8) ◽  
pp. 1134-1144 ◽  
Author(s):  
Ioanna Giopanou ◽  
Nikolaos I Kanellakis ◽  
Anastasios D Giannou ◽  
Ioannis Lilis ◽  
Antonia Marazioti ◽  
...  

Abstract Increased expression of osteopontin (secreted phosphoprotein 1, SPP1) is associated with aggressive human lung adenocarcinoma (LADC), but its function remains unknown. Our aim was to determine the role of SPP1 in smoking-induced LADC. We combined mouse models of tobacco carcinogen-induced LADC, of deficiency of endogenous Spp1 alleles, and of adoptive pulmonary macrophage reconstitution to map the expression of SPP1 and its receptors and determine its impact during carcinogenesis. Co-expression of Spp1 and mutant KrasG12C in benign cells was employed to investigate SPP1/KRAS interactions in oncogenesis. Finally, intratracheal adenovirus encoding Cre recombinase was delivered to LSL.KRASG12D mice lacking endogenous or overexpressing transgenic Spp1 alleles. SPP1 was overexpressed in experimental and human LADC and portended poor survival. In response to two different smoke carcinogens, Spp1-deficient mice developed fewer and smaller LADC with decreased cellular survival and angiogenesis. Both lung epithelial- and macrophage-secreted SPP1 drove tumor-associated inflammation, while epithelial SPP1 promoted early tumorigenesis by fostering the survival of KRAS-mutated cells. Finally, loss and overexpression of Spp1 was, respectively, protective and deleterious for mice harboring KRASG12D-driven LADC. Our data support that SPP1 is functionally involved in early stages of airway epithelial carcinogenesis driven by smoking and mutant KRAS and may present an important therapeutic target.


2019 ◽  
Vol 234 (9) ◽  
pp. 16021-16031 ◽  
Author(s):  
Pranjal Kumar ◽  
Seema Khadirnaikar ◽  
Sudhanshu Kumar Shukla

2018 ◽  
Vol 14 (22) ◽  
pp. 2253-2263 ◽  
Author(s):  
Ningyu Huang ◽  
Wenbo Lin ◽  
Xiuyu Shi ◽  
Tao Tao

2012 ◽  
Vol 73 (2) ◽  
pp. 756-766 ◽  
Author(s):  
Junchao Cai ◽  
Jueheng Wu ◽  
Huizhong Zhang ◽  
Lishan Fang ◽  
Yongbo Huang ◽  
...  

2007 ◽  
Vol 2 (8) ◽  
pp. S423 ◽  
Author(s):  
Mee Sook Roh ◽  
Akihiko Yoshizawa ◽  
Junya Fukuoka ◽  
Konstantin Shilo ◽  
Takeshi Fujii ◽  
...  

2018 ◽  
Author(s):  
Erh-Hsuan Lin ◽  
Chiung-Fang Hsu ◽  
Yi-Hua Jan ◽  
Tsung-Hsien Lin ◽  
Hsiang-Yi Chang ◽  
...  

AbstractLung cancer is the leading cause of cancer-associated death worldwide. Early metastasis and the recurrence remain major challenges for lung cancer treatment in clinic. Targeting the cancer stemness could be a potential strategy to restrain tumor progression. In the current study, we found that in lung adenocarcinoma (LAC), BMI1 and MCL1 play crucial roles in invasion, chemo-resistance, and tumor initiation. JNK signaling is a link between oncogenic pathway or environment stress to cancer stemness. The activation of JNK, either by EGFR or chemotherapy agent, stabilized BMI1 and MCL1 proteins through suppressing the expression of E3-ubiquitin ligase HUWE1. In lung cancer patient samples, high level of BMI1 is correlated with poor survival, and the expression of BMI1 is positively correlated with MCL1. A novel small-molecule BI-44 was synthesized, which effectively suppressed BMI1/MCL1 expression and inhibited tumor formation and progression in preclinical models. Targeting BMI1/MCL1 provides the basis for a new therapeutic approach in the treatment of LAC.


Oncotarget ◽  
2016 ◽  
Vol 7 (26) ◽  
pp. 39970-39979 ◽  
Author(s):  
Jun Huang ◽  
Xing-Xing Fan ◽  
Jiaxi He ◽  
Hui Pan ◽  
Run-Ze Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document